Taiwan’s achievements in eliminating hepatitis C virus (HCV) have once again gained international recognition. On October 9, 2026, The Lancet, a world-renowned medical journal published online a letter to the editor titled "Taiwan's path to hepatitis C elimination", which was subsequently included in the printed issue on October 10. Co-authored by Minister of Health and Welfare Chung-Liang Shih, Deputy Minister Jen-Hsiang Chuang, and Director-General of the Health Promotion Administration Ching-Fen Shen, the article highlights Taiwan’s policy experiences and milestones in HCV elimination with the global community.
With sustained policy support under the administrations of former President Tsai Ing-wen and President Lai Ching-te, and successive Premiers and Ministers of Health and Welfare, Taiwan has progressively expanded HCV screening, diagnosis, and treatment services. By 2025, Taiwan had surpassed the World Health Organization (WHO) Path to Elimination (PTE) Gold Tier thresholds for key programmatic elimination indicators, marking a significant milestone in public health.
Taiwan’s comprehensive cascade of care—built through the systematic integration of screening, diagnosis, and treatment, targeted precision interventions for high-risk populations, disease-surveillance and information networks, and cross-sectoral collaboration—serves as a strong model for integrated public-health delivery. In recent years, a downward trend in liver cancer incidence and mortality has been observed, demonstrating that the sustained execution of integrated elimination strategies effectively reduces long-term liver disease burden. Taiwan’s experience demonstrates that HCV elimination is an achievable goal through comprehensive, sustained, and coordinated public health efforts.
Strategies Advancing Taiwan Toward WHO HCV Elimination Targets
1. Precision Public Health for Prevention and Control
The Health Promotion Administration (HPA) has expanded access to comprehensive hepatitis B and C screening through targeted public health initiatives.
2. Universal National Health Insurance Coverage for Direct-Acting Antivirals (DAAs)
Since 2017, the National Health Insurance Administration (NHIA) has provided coverage for highly effective DAAs under Taiwan’s National Health Insurance program. In 2019, restrictions on reimbursement based on liver fibrosis stage were completely removed. Screening services were also integrated into adult preventive health checkups to reduce barriers to diagnosis and treatment.
As of December 2025, the diagnosis rate among people living with chronic HCV infection had reached 92.4%, while 92.7% of those diagnosed had received treatment. Both indicators exceeded the WHO PTE Gold Tier thresholds of at least 80% for diagnosis and 70% for treatment. They also surpassed the WHO's 2030 global HCV elimination targets of at least 90% for diagnosis and 80% for treatment.
3. Micro-Elimination and Precision Interventions for High-Risk Populations
Treatment coverage has reached 95% among key high-risk populations, including patients receiving dialysis for end-stage renal disease, individuals receiving methadone maintenance treatment, and people living with HIV. For people who inject drugs (PWID), harm reduction programs provide an annual average of more than 150 sterile syringes per person, meeting the WHO PTE Gold Tier threshold. In addition, nationwide screening of all blood donations and universal implementation of safe medical injection practices have been maintained.
4. Integrated Access to Screening and Treatment through Cross-Sectoral Collaboration
With dedicated national budgetary support, Taiwan has expanded access to medical services in remote and mountainous communities. In parallel, hospital-based surveillance initiatives have been established to monitor trends in mortality associated with chronic liver disease and cirrhosis caused by hepatitis B and C.
Through the development of an integrated information network connecting data across multiple government agencies, Taiwan has strengthened cross-sectoral coordination and public-private partnerships at the central, local, and community levels. These coordinated efforts have accompanied sustained declines in liver cancer incidence and mortality, demonstrating the value of integrated public health governance.
Translating the "Taiwan Model" into Transferable Public Health Governance Experience
Since 2018, the Ministry of Health and Welfare has promoted the "National Hepatitis C Policy Guideline (2018–2025)", adopting a strategy of using treatment to drive prevention and coupling screening with control. Early this year, Taiwan submitted the official Taiwan Hepatitis C Elimination Report to the WHO Regional Office for the Western Pacific (WPRO), demonstrating its commitment to global health.
During the 79th World Health Assembly (WHA79) in May 2026, the MOHW hosted an international forum on HCV in Geneva, Switzerland, highlighting Taiwan’s active engagement in global health initiatives. International experts and scholars attending the forum recognized Taiwan’s progress in HCV elimination, particularly its application of precision public health strategies and reforms to the National Health Insurance system. Their recognition underscored the significance of Taiwan’s experience as both a national public health achievement and a potential reference for other countries pursuing HCV elimination.
Moving forward, the MOHW will continue to leverage established international health cooperation platforms, uphold the spirit of "Taiwan Can Help", and share Taiwan’s public health expertise and experience to contribute to global efforts toward HCV elimination.
Read the Letter to the Editor, "Taiwan's Path to Hepatitis C Elimination", published in The Lancet:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01812-X/fulltext*
*Letters published in the Correspondence section represent the views of their authors and do not necessarily reflect the views of The Lancet journals. Letters to the Editor are not normally subject to external peer review.